Baseline characteristics for all patients
| Variable . | Total, n = 399 . | Serum and urine, n = 241 . | Serum only, n = 103 . | Urine only, n = 55 . |
|---|---|---|---|---|
| Percentage of total | 100% | 60% | 26% | 14% |
| Male, % | 64.7 | 68.0 | 63.1 | 52.7 |
| Age, y | 63.1 (23.8-83.5) | 63.7 (34.7-83.5) | 62.7 (23.8-76.2) | 59.3 (32.5-82.1) |
| Serum creatinine, mg/dL | 1.2 (0.5-4.9) | 1.3 (0.5-4.9) | 1.1 (0.7-2.2) | 1.3 (0.6-4.7) |
| Serum heavy chain, % | ||||
| IgG | 58.6 | 68.1 | 68.0 | 0 |
| IgA | 24.6 | 27 | 32.0 | 0 |
| IgD | 0.2 | 0.8 | 0 | 0 |
| none | 13.8 | 0 | 0 | 100 |
| missing | 2.5 | 4.2 | 0 | 0 |
| Serum M-spike | ||||
| n | 337 | 235 | 102 | 0 |
| Median (range), g/dL | 4.0 (1.0-10.0) | 4.1 (1.0-10.0) | 3.9 (1.4-9.4) | NA |
| Light chain clonality κ/λ, % | 66.4/33.6 | 65.6/34.4 | 68.9/31.1 | 65.6/34.5 |
| Serum FLC | ||||
| n | 399 | 241 | 103 | 55 |
| Involved, mg/dL | 37.2 (0.25-3370) | 47.9 (0.75-3290) | 7.21 (0.25-642) | 286 (7.49-3370) |
| Uninvolved, mg/dL | 0.66 (0.01-13.1) | 0.76 (0.01-12.1) | 0.65 (0.02-13.1) | 0.44 (0.04-1.77) |
| Difference of involved − uninvolved, mg/dL | 36 (0.03-3369) | 47.1 (0.4-3285) | 6.04 (0.03-641) | 284 (7.26-3368) |
| Ratio of involved/uninvolved | 69.0 (1.03-28406) | 82.6 (1.04-28 406) | 13.6 (1.03-10 000) | 613 (17.4-17 400) |
| Involved more than 10 mg/dL, % | 71 | 78 | 41 | 98 |
| Difference of involved minus uninvolved more than 5 mg/dL, % | 80 | 86 | 53 | 100 |
| ISS, % | ||||
| I | 47.1 | 40.7 | 64.1 | 43.6 |
| II | 25.3 | 27.0 | 23.8 | 21.8 |
| III | 27.6 | 32.4 | 11.8 | 34.6 |
| Serum β2-microglobulin, mg/L | 3.6 (0.6-64) | 4.1 (0.6-64) | 2.7 (0.8-13.4) | 4.2 (0.6-16.9) |
| Urine M-spike | ||||
| n | 227 | 173 | 0 | 54 |
| Median (range), g/24 hr | 0.94 (0.01-22.7) | 0.59 (0.01-13.7) | NA | 3.13 (0.05-22.7) |
| BM plasma cells | ||||
| n | 389 | 234 | 102 | 53 |
| Median (range), % | 40 (2-99) | 44 (2-99) | 35 (4-99) | 43 (6-99) |
| Variable . | Total, n = 399 . | Serum and urine, n = 241 . | Serum only, n = 103 . | Urine only, n = 55 . |
|---|---|---|---|---|
| Percentage of total | 100% | 60% | 26% | 14% |
| Male, % | 64.7 | 68.0 | 63.1 | 52.7 |
| Age, y | 63.1 (23.8-83.5) | 63.7 (34.7-83.5) | 62.7 (23.8-76.2) | 59.3 (32.5-82.1) |
| Serum creatinine, mg/dL | 1.2 (0.5-4.9) | 1.3 (0.5-4.9) | 1.1 (0.7-2.2) | 1.3 (0.6-4.7) |
| Serum heavy chain, % | ||||
| IgG | 58.6 | 68.1 | 68.0 | 0 |
| IgA | 24.6 | 27 | 32.0 | 0 |
| IgD | 0.2 | 0.8 | 0 | 0 |
| none | 13.8 | 0 | 0 | 100 |
| missing | 2.5 | 4.2 | 0 | 0 |
| Serum M-spike | ||||
| n | 337 | 235 | 102 | 0 |
| Median (range), g/dL | 4.0 (1.0-10.0) | 4.1 (1.0-10.0) | 3.9 (1.4-9.4) | NA |
| Light chain clonality κ/λ, % | 66.4/33.6 | 65.6/34.4 | 68.9/31.1 | 65.6/34.5 |
| Serum FLC | ||||
| n | 399 | 241 | 103 | 55 |
| Involved, mg/dL | 37.2 (0.25-3370) | 47.9 (0.75-3290) | 7.21 (0.25-642) | 286 (7.49-3370) |
| Uninvolved, mg/dL | 0.66 (0.01-13.1) | 0.76 (0.01-12.1) | 0.65 (0.02-13.1) | 0.44 (0.04-1.77) |
| Difference of involved − uninvolved, mg/dL | 36 (0.03-3369) | 47.1 (0.4-3285) | 6.04 (0.03-641) | 284 (7.26-3368) |
| Ratio of involved/uninvolved | 69.0 (1.03-28406) | 82.6 (1.04-28 406) | 13.6 (1.03-10 000) | 613 (17.4-17 400) |
| Involved more than 10 mg/dL, % | 71 | 78 | 41 | 98 |
| Difference of involved minus uninvolved more than 5 mg/dL, % | 80 | 86 | 53 | 100 |
| ISS, % | ||||
| I | 47.1 | 40.7 | 64.1 | 43.6 |
| II | 25.3 | 27.0 | 23.8 | 21.8 |
| III | 27.6 | 32.4 | 11.8 | 34.6 |
| Serum β2-microglobulin, mg/L | 3.6 (0.6-64) | 4.1 (0.6-64) | 2.7 (0.8-13.4) | 4.2 (0.6-16.9) |
| Urine M-spike | ||||
| n | 227 | 173 | 0 | 54 |
| Median (range), g/24 hr | 0.94 (0.01-22.7) | 0.59 (0.01-13.7) | NA | 3.13 (0.05-22.7) |
| BM plasma cells | ||||
| n | 389 | 234 | 102 | 53 |
| Median (range), % | 40 (2-99) | 44 (2-99) | 35 (4-99) | 43 (6-99) |
Data are medians (range), except where specified. There were no differences among the groups with the exception of a lower ISS risk in the serum-only patients and higher involved FLC levels in the urine-only group.
NA indicates not applicable.